Redhill Biopharma
RDHL
16 hedge funds and large institutions have $720K invested in Redhill Biopharma in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 15 → 16 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
49% less capital invested
Capital invested by funds: $1.4M → $720K (-$683K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$48.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$40.7K |
| 3 |
Jane Street
New York
|
+$20.9K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$9.56K |
| 5 |
VF
Virtu Financial
New York
|
+$7.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$434K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$5K |
| 3 |
GS
Gagnon Securities
New York
|
-$1.03K |
| 4 |
APC
Aspire Private Capital
Cornelius,
North Carolina
|
-$215 |
| 5 |
Morgan Stanley
New York
|
-$78 |
RDHL Hedge Fund Activity: Q2 2024 in Review
16 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q2 2024, worth a combined $720K — down 49% from $1.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new RDHL positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $48.2K. The largest seller was Sabby Management, cutting an estimated $434K.
- 16 institutional investors held Redhill Biopharma (RDHL) as of Q2 2024, up from 15 in Q1 2024.
- Funds reported $720K of Redhill Biopharma stock for Q2 2024, down 49% quarter-over-quarter.
- 3 funds opened new Redhill Biopharma positions in Q2 2024 and 2 closed out, a net change of +1 holder.
- The largest Redhill Biopharma buyer in Q2 2024 was Citadel Advisors, an estimated $48.2K added.
- The largest Redhill Biopharma seller in Q2 2024 was Sabby Management, an estimated $434K sold.
Based on aggregated 13F filings for Q2 2024.